Inhibitory checkpoint inhibitors (αPD-1/PD-L1 and anti-CTLA-4) are used in daily practice for the treatment of advanced malignancies, including melanoma and non-small cell lung cancer (NSCLC)12. This evidence concerns the gene CD274 and non-small cell lung carcinoma.